THIENOPYRIMIDINONE DERIVATIVES AS mGluR1 ANTAGONISTS
申请人:KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
公开号:US20140228565A1
公开(公告)日:2014-08-14
Disclosed are thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. Also disclosed are methods for preparing the thienopyrimidinone derivatives, and pharmaceutical compositions containing the thienopyrimidinone derivatives as active ingredients.
subtype 1 (mGluR1) is a potential target for the treatment of neuropathic pain, and there has been much effort to discover mGluR1antagonists. In this study, a series of N 3‐alkyl‐thienopyrimidin‐4‐ones were prepared by introducing various alkyl and aryl groups to the N 3‐ and 7‐positions of the thienopyrimidin‐4‐one core structure, respectively, and their inhibitory activities against mGluR1 were biologically
[EN] THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD<br/>[FR] COMPOSES THERAPEUTIQUES DANS LESQUELS LA PYRIDINE EST UTILISEE COMME SQUELETTE
申请人:ASTRAZENECA AB
公开号:WO2005115986A1
公开(公告)日:2005-12-08
Compounds of formulas I, IA, and IB or IC or pharmaceutically acceptable salts thereof: wherein A, A1, A2, A3, A4, R2, R3, R4 and n are as defined in the specifications well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
[EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
申请人:BORAGEN INC
公开号:WO2021003501A1
公开(公告)日:2021-01-07
The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. Compounds of the disclosure have activity as dual modulators of Janus kinase (JAK), alone, or in combination with one or more of an additional mechanism, including a tyrosine kinase, such as TrkA or Syk, and PDE4, and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK and PDE4 by administering a compound herein described.
Versatile routes for synthesis of diarylamines through acceptorless dehydrogenative aromatization catalysis over supported gold–palladium bimetallic nanoparticles
palladium nanoparticle catalyst (Pd/TiO2) gave the desired diarylamines, the catalyticactivity was inferior to that of Au–Pd/TiO2. Moreover, the activity of Au–Pd/TiO2 was superior to that of a physical mixture of Au/TiO2 and Pd/TiO2. The present Au–Pd/TiO2-catalyzed transformation of cyclohexylamines proceeds through complex pathways comprising amine dehydrogenation, imine disproportionation, and condensation